Prognostic Significance of Serum Inflammatory Response Markers in Newly Diagnosed Non-Small Cell Lung Cancer before Chemoirradiation

Tolia, Maria; Tsoukalas, Nikolaos; Kyrgias, George; Mosa, Eftychia; Maras, Apostolos; Kokakis, Ioannis; Liakouli, Zoi; Kouvaris, John; Liaskonis, Konstantinos; Charalampakis, Nikolaos; Pistevou-Gombaki, Kyriaki; Kelekis, Nikolaos; Kouloulias, Vassilis

doi:10.1155/2015/485732

Cited by 18 publications

(10 citation statements)

References 19 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was identified that a lower serum ALB level is an independent indicator of a poorer survival in various types of cancer (42). For instance, Tolia et al (43) indicated that the serum ALB level was significantly associated with OS in univariate analysis. Additionally, Jin et al (44) analyzed 101 samples from patients with stage I NSCLC and concluded that patients with low pre-operative ALB levels (<35 g/l) had a significantly poorer survival rate than patients with normal pre-operative serum ALB levels (≥35 g/l).…”

Section: Discussionmentioning

confidence: 99%

Prognostic evaluation of patients with resectable lung cancer using systemic inflammatory response parameters

et al. 2018

View full text Add to dashboard Cite

Lung cancer is one of the leading causes of cancer-associated mortality. C-reactive protein (CRP), albumin (ALB), globulin (GLB), lactate dehydrogenase (LDH), neutrophil-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been identified as general parameters for systemic inflammatory response (SIR). Furthermore, these parameters are also associated with tumor development and metastasis. The present study aimed to investigate the predictive values of these SIR parameters in patients with resectable lung cancer. In total, 101 patients with resectable lung cancer were recruited in the present study. The patients were divided into two groups according to the median value of pre-treatment CRP, ALB, GLB, LDH, NLR or PLR values. The post-/pre-treatment ratios were defined as the ratio of pre-treatment blood parameter values and the corresponding values obtained following therapy. A ratio of ≤1.1 indicated that the values were not increased, while a ratio of >1.1 suggested that the values were increased following treatment. Patients with lower pre-treatment ALB levels had poorer overall survival (OS) rates, whereas GLB, LDH, CRP, NLR or PLR levels were not associated with outcomes. Whole course treatment (surgery combined with adjuvant chemotherapy) significantly increased the value of ALB, but decreased the value of NLR, whereas it had no effect on the values of LDH, CRP or PLR. Post-/pre-treatment LDH and PLR were associated with outcomes. Post-/pre-treatment ALB, GLB, CRP and NLR were not associated with outcomes. Multivariate analysis revealed that a low pre-treatment ALB level and increased post-/pre-treatment PLR were independent risk factors affecting OS. The receiver operating characteristic curve analysis demonstrated that an ALB value of 47.850 g/l was considered to be the optimal cut-off value for prognosis; the sensitivity was 28.8% and specificity was 95.9%. It was suggested that the pre-treatment ALB and post-/pre-treatment PLR may be potential prognostic factors in resectable lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic evaluation of patients with resectable lung cancer using systemic inflammatory response parameters

et al. 2018

View full text Add to dashboard Cite

show abstract

“…However, there were few studies regarding the effect of the CAR on prognosis in patients with lung cancer. [19–23] Therefore, we collected the available publications and conducted a meta-analysis to investigate whether CAR has a prognostic value in patients with lung cancer in this present study.…”

Section: Introductionmentioning

confidence: 99%

The prognostic value of C-reactive protein to albumin ratio in patients with lung cancer

et al. 2018

View full text Add to dashboard Cite

Background:To perform a meta-analysis of retrospective studies exploring the association of C-reactive protein to albumin (CAR) with overall survival (OS) in patients with lung cancer.Methods:Relevant studies were enrolled by searching databases of PubMed, Cochrane Library, Web of Science, and Embase were searched until July 16, 2017. We combined the hazard ratios (HRs) and 95% confidence intervals (CIs) to assess the correlation between CAR and OS in patients with lung cancerResults:Four studies involving 1257 participants from several countries were involved in the meta-analysis. In a pooled analysis of all studies, elevated CAR predicted poor OS (HR: 2.13; 95% CI: 1.52–2.97; P < .05). Subgroup analysis showed that high level of CAR predicted poor OS in patients with lung cancer though multivariate analyses on 1092 participants (HR: 1.63; 95% CI: 1.24–2.51; P < .001) and the heterogeneity decreased to 45.4%. Moreover, a similar trend was observed in patients receiving surgery (HR: 2.64; 95% CI: 2.08–3.35; P < .001) and chemotherapy (HR: 1.75; 95% CI: 1.93–2.57; P = .004). And the HRs for patients receiving surgery was moderately higher than that for patients receiving chemotherapy.Conclusion:Our findings indicate that CAR may have a prognostic value in lung cancer as we detected a significant association between elevated CAR and poorer OS. However, further studies are warranted to draw firm conclusions.

show abstract

“…Actual activities of the immune functions and homeostasis in medullar immunological microenvironment in the body are di cult to be measured. To date, for different cancer several in ammatory markers has been reported, like CRP (25), albumin (26), neutrophil-to-lymphocyte ratio (NLR) (27), and platelet-tolymphocyte ratio (PLR) (28). Recent studies on the effects of NLR on prognosis of MM patients have been reported (22,23).…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of advanced lung cancer inflammation index (ALI) in multiple myeloma patients – a retrospective study

Huang

Yan

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Advanced lung cancer inflammation index (ALI) is known to predict the overall survival of patients having some solid tumors or B-cell lymphoma. The study investigates the predictive value of ALI in multiple myeloma (MM) patients and the correlation between ALI and prognosis.Methods: A database of 269 MM consecutive patients who underwent chemotherapy between December 2011 and June 2019 in the Affiliated Hospital of Qingdao University was reviewed. ALI cut-off value calculated before the initial chemotherapy and post 4 courses treatment were identified according to the receiver operating characteristic (ROC) curve, and its association with clinical characteristics, treatment response, overall survival (OS), and progression-free survival (PFS) were assessed.Results: Patients in the low ALI group (n=147) had higher risk of β2 microglobulin elevation, more advanced ISS (International Classification System stage), and TP53 gene mutation, with significantly lower median overall survival (OS; 36.29 vs. 57.92 months, P = 0.010) and progression-free survival (PFS; 30.94 vs. 35.67 months, P = 0.013). Independent risk factors influencing the OS of MM patients were ALI (P = 0.007), extramedullary infiltration (P = 0.001), TP53 (P = 0.020), Plt (P = 0.005), and bone destruction (P = 0.024). ALI (P = 0.005), extramedullary infiltration (P = 0.004), TP53 (P = <0.001), Plt (P = 0.017), and complex chromosome karyotype (P = 0.010) were independent risk factors influencing the PFS of MM patients.Conclusions: ALI is a potential independent risk factor predicting the prognosis of newly diagnosed MM patients.

show abstract

Prognostic Significance of Serum Inflammatory Response Markers in Newly Diagnosed Non-Small Cell Lung Cancer before Chemoirradiation

Cited by 18 publications

References 19 publications

Prognostic evaluation of patients with resectable lung cancer using systemic inflammatory response parameters

Prognostic evaluation of patients with resectable lung cancer using systemic inflammatory response parameters

The prognostic value of C-reactive protein to albumin ratio in patients with lung cancer

Prognostic significance of advanced lung cancer inflammation index (ALI) in multiple myeloma patients – a retrospective study

Contact Info

Product

Resources

About